Jul 8 2015
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, today announced that it will be presenting at the 12th Anti-Infectives Partnering and Deal Making Conference being held July 9-10, 2015, in Boston, MA.
Raphael J. Mannino, Ph.D., Associate Professor of Pathology and Laboratory Medicine at Rutgers University, New Jersey Medical School, and a member of the Matinas BioPharma Scientific Advisory Board, will present on Friday, July 10, 2015, at noon during the "Trends in Anti-Infectives Marketplace" session.
Dr. Mannino's presentation entitled, "Novel Technology to Combat Drug-Resistant Infections," will focus on the significant worldwide health threat posed by rapidly spreading drug-resistant fungal and bacterial strains. During this presentation, he will discuss the Company's focus on developing lipid-crystal nano-particle cochleate formulations of approved highly potent, but very toxic, anti-fungal and anti-bacterial medications to provide new solutions for physicians to combat increasing drug-resistance.
Matinas BioPharma's proprietary cochleate formulation platform technology has three main benefits: (i) the solid, highly stable, lipid-crystal particle shields sensitive organs from toxic effects of anti-fungal and anti-bacterial drugs, (ii) it uses the body's natural defense systems to target delivery to the site of infection or inflammation, and (iii) it permits oral administration of currently injectable-only medications.
Pre-clinical animal studies with several anti-infective medications in cochleate formulations have demonstrated the promise and value of the Company's technology, resulting in collaborations with the National Institutes of Health/National Institute of Allergy and Infectious Disease ("NIH/NIAID"), which will initiate later stage clinical trials this year with this technology. With the broad applicability of the cochleate drug delivery platform and pre-clinical data across many therapeutic areas, including antivirals, vaccines and anti-inflammatories, Matinas BioPharma believes there are many medications already approved and in development with significant toxicity which stand to benefit from its cochleate platform and an improved clinical profile.
Source: http://www.matinasbiopharma.com/